Welcome to E-Menai

--(BUSINESS ambien to come down from adderall WIRE)--Jun 22, 2009 - Kowa Pharmaceuticals America, Inc. Food and Drug Administration (FDA) has approved Cambia, a diclofenac-based non-steroidal anti-inflammatory drug ("NSAID") combined with potassium bicarbonate, for the treatment of acute migraine with or without aura in adults. About Applied Pharma Research APR Applied Pharma Research SA is an independent, international, vertically integrated ambien to come down from adderall drug delivery and drug development company in healthcare with registered offices in Switzerland and the U.S. The Companies plan to meet with the FDA following submission of their response. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act").